Researchers from Ohio State University, led by Distinguished Professor John J. Coccyx and graduate student Arshad Ahmad from Heritage College of Osteopathic Medicine have discovered a potential new ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for a nuanced ...
Lung cancer is now the leading cause of cancer deaths in the United States, claiming more lives than several other major ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results